Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2012 2
2016 3
2017 6
2018 4
2019 13
2020 1043
2021 1457
2022 658
Text availability
Article attribute
Article type
Publication date

Search Results

2,874 results
Results by year
Filters applied: . Clear all
Page 1
Remdesivir: First Approval.
Lamb YN. Lamb YN. Drugs. 2020 Sep;80(13):1355-1363. doi: 10.1007/s40265-020-01378-w. Drugs. 2020. PMID: 32870481 Free PMC article. Review.
The antiviral agent remdesivir (Veklury(); Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. ...Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus far y …
The antiviral agent remdesivir (Veklury(); Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses …
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ, Kebriaei R, Dresser LD. Jorgensen SCJ, et al. Pharmacotherapy. 2020 Jul;40(7):659-671. doi: 10.1002/phar.2429. Epub 2020 Jun 28. Pharmacotherapy. 2020. PMID: 32446287 Free PMC article. Review.
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being eval …
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has …
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
Aleissa MM, Silverman EA, Paredes Acosta LM, Nutt CT, Richterman A, Marty FM. Aleissa MM, et al. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01814-20. doi: 10.1128/AAC.01814-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33139290 Free PMC article. Review.
Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). ...This article examines the available literature describing remdesivir's pharmacology, pharmacokinetics, and pr
Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus dise
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Singh AK, Singh A, Singh R, Misra A. Singh AK, et al. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):641-648. doi: 10.1016/j.dsx.2020.05.018. Epub 2020 May 12. Diabetes Metab Syndr. 2020. PMID: 32428865 Free PMC article. Review.
BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe C …
BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In …
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O, Lai WF. Sreekanth Reddy O, et al. Chembiochem. 2021 Mar 16;22(6):939-948. doi: 10.1002/cbic.202000595. Epub 2020 Nov 11. Chembiochem. 2021. PMID: 33031623 Free PMC article. Review.
This article provides an overview of the life cycle and routes of transmission of SARS-CoV-2. The therapeutic effects of two drugs [i. e., remdesivir (RDV) and favipiravir (FPV)] which can potentially tackle COVID-19 are discussed based on current published data. ...
This article provides an overview of the life cycle and routes of transmission of SARS-CoV-2. The therapeutic effects of two drugs [i. e., …
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Wang Y, et al. Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Lancet. 2020. PMID: 32423584 Free PMC article. Clinical Trial.
Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.75]). ...Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stop
Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.75]). ...Advers
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Spinner CD, et al. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. JAMA. 2020. PMID: 32821939 Free PMC article. Clinical Trial.
Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group. ...By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and …
Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir
Remdesivir in The Treatment of COVID-19.
Rosenberg K. Rosenberg K. Am J Nurs. 2021 Jan 1;121(1):55. doi: 10.1097/01.NAJ.0000731668.01845.8c. Am J Nurs. 2021. PMID: 33350698 Clinical Trial.
According to this study: The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19.A variety of therapeutic approaches are needed to continue to improve outcomes in COVID-19 patients....
According to this study: The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19.A va …
The place for remdesivir in COVID-19 treatment.
Young B, Tan TT, Leo YS. Young B, et al. Lancet Infect Dis. 2021 Jan;21(1):20-21. doi: 10.1016/S1473-3099(20)30911-7. Epub 2020 Nov 26. Lancet Infect Dis. 2021. PMID: 33248473 Free PMC article. No abstract available.
Remdesivir: From Ebola to COVID-19.
Santoro MG, Carafoli E. Santoro MG, et al. Biochem Biophys Res Commun. 2021 Jan 29;538:145-150. doi: 10.1016/j.bbrc.2020.11.043. Epub 2020 Nov 19. Biochem Biophys Res Commun. 2021. PMID: 33388129 Free PMC article. Review.
After in vitro studies had shown its antiviral activity against SARS-CoV-2, and a first patient was successfully treated with the drug in the USA, a number of trials on remdesivir were initiated. Several had encouraging results, particularly the ACTT-1 double blind, random …
After in vitro studies had shown its antiviral activity against SARS-CoV-2, and a first patient was successfully treated with the drug in th …
2,874 results